Vtv Therapeutics Financials
Vtv Therapeutics (VTVT) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
vTv’s dominant business mechanic is equity-funded R&D, with cash raising outrunning operating burn and dwarfing any revenue base.
External financing, not commercial revenue, is funding the company’s operating model: after burning about$25.3M in operations in both FY2024 and FY2025, it brought in roughly$130.0M of financing cash across those two years. That imbalance rebuilt the balance sheet from a prior capital deficit to positive equity of$64.4M and lifted cash to$88.9M , so fundraising is doing the economic heavy lifting that sales are not.
With
The loss is largely a cash loss, not just a non-cash accounting result: FY2025 net loss of
Financial Health Signals
Vtv Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Vtv Therapeutics scores -2.08, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($131.5M) relative to total liabilities ($25.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Vtv Therapeutics passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
Vtv Therapeutics reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Vtv Therapeutics reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Vtv Therapeutics generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Vtv Therapeutics's EBITDA was -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.1% from the prior year.
Vtv Therapeutics reported -$27.0M in net income in fiscal year 2025. This represents a decrease of 46.1% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Vtv Therapeutics held $88.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Vtv Therapeutics's ROE was -41.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 109.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Vtv Therapeutics invested $17.9M in research and development in fiscal year 2025. This represents an increase of 54.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
VTVT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0-100.0% | $1.0M | $0-100.0% | $2.0M-49.6% | $4.0M-37.6% | $6.4M+132.1% | $2.8M-77.8% | $12.4M+4172.9% | $291K-54.1% | $634K+22.2% | $519K-66.5% | $1.5M+58.7% | $976K |
| R&D Expenses | N/A | $17.9M+54.7% | $11.5M-15.1% | $13.6M+10.0% | $12.4M-7.3% | $13.3M+21.0% | $11.0M-27.1% | $15.1M-34.4% | $23.0M-41.9% | $39.6M-11.8% | $45.0M+65.0% | $27.2M+56.7% | $17.4M-22.0% | $22.3M |
| SG&A Expenses | N/A | $14.9M+9.5% | $13.7M+14.6% | $11.9M-2.4% | $12.2M-1.2% | $12.3M+70.2% | $7.3M-15.1% | $8.5M-7.4% | $9.2M-18.6% | $11.3M+14.4% | $9.9M+9.1% | $9.1M-22.5% | $11.7M+3.0% | $11.4M |
| Operating Income | N/A | -$32.8M-35.7% | -$24.2M+5.2% | -$25.5M-13.1% | -$22.5M-4.1% | -$21.7M-82.8% | -$11.9M+43.3% | -$20.9M-5.4% | -$19.8M+60.9% | -$50.7M+7.9% | -$55.0M-44.3% | -$38.1M-32.0% | -$28.9M+19.4% | -$35.8M |
| Interest Expense | N/A | $6K | $0-100.0% | $13K-13.3% | $15K+25.0% | $12K-98.3% | $692K-62.1% | $1.8M-44.5% | $3.3M+6.4% | $3.1M+676.9% | $398K+268.5% | $108K-62.2% | $286K-39.9% | $476K |
| Income Tax | N/A | $0-100.0% | $100K | $0-100.0% | $200K+73.9% | $115K | $0-100.0% | $100K-50.0% | $200K-75.0% | $800K | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$27.0M-46.1% | -$18.5M+8.8% | -$20.3M-5.7% | -$19.2M-47.6% | -$13.0M-52.8% | -$8.5M+34.8% | -$13.0M-64.9% | -$7.9M+51.0% | -$16.1M+1.3% | -$16.4M+40.5% | -$27.5M+23.8% | -$36.1M+25.1% | -$48.2M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VTVT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $89.9M+134.9% | $38.3M+247.3% | $11.0M-66.9% | $33.2M+30.5% | $25.5M+72.2% | $14.8M+59.6% | $9.3M+8.3% | $8.6M-69.3% | $27.9M-48.8% | $54.5M-40.5% | $91.5M+606.8% | $13.0M | N/A |
| Current Assets | $89.9M+135.9% | $38.1M+257.6% | $10.7M-60.7% | $27.1M+73.4% | $15.6M+116.5% | $7.2M+154.2% | $2.8M-18.3% | $3.5M-82.9% | $20.4M-60.9% | $52.1M-41.6% | $89.2M+5436.1% | $1.6M | N/A |
| Cash & Equivalents | $88.9M+142.0% | $36.7M+289.0% | $9.4M-22.1% | $12.1M-9.6% | $13.4M+133.4% | $5.7M+223.4% | $1.8M+5.6% | $1.7M-85.7% | $11.8M-77.2% | $51.5M-41.5% | $88.0M+6258.6% | $1.4M+27.1% | $1.1M |
| Accounts Receivable | N/A | $62K-39.2% | $102K-41.0% | $173K+203.5% | $57K-63.9% | $158K+3060.0% | $5K | $0-100.0% | $8.0M | $0-100.0% | $69K | N/A | N/A |
| Total Liabilities | $25.5M+6.2% | $24.0M-32.9% | $35.7M-18.8% | $44.0M+24.9% | $35.2M-62.9% | $94.9M+62.8% | $58.3M-36.2% | $91.4M-48.9% | $179.0M+23.1% | $145.4M-14.2% | $169.5M-66.9% | $511.8M | N/A |
| Current Liabilities | $6.6M+27.8% | $5.2M-51.1% | $10.6M+37.8% | $7.7M-9.3% | $8.5M+33.0% | $6.4M-52.2% | $13.4M-29.0% | $18.8M-30.0% | $26.9M+135.5% | $11.4M+48.0% | $7.7M+12.6% | $6.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $5.0M-66.6% | $15.1M | N/A | $11.1M | N/A | $2.1M | N/A |
| Total Equity | $64.4M+428.2% | $12.2M+149.4% | -$24.7M-129.8% | -$10.7M-10.3% | -$9.7M+87.8% | -$80.1M-63.4% | -$49.0M+40.8% | -$82.9M+45.1% | -$151.0M-66.1% | -$90.9M-16.6% | -$78.0M+84.4% | -$498.8M-64.2% | -$303.7M |
| Retained Earnings | -$326.7M-9.0% | -$299.7M-6.6% | -$281.0M-5.8% | -$265.5M-6.7% | -$248.8M+14.2% | -$290.0M-24.2% | -$233.5M+0.2% | -$233.9M+16.2% | -$279.1M-29.5% | -$215.5M-10.0% | -$196.0M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill.
VTVT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.8M | -$25.3M+0.2% | -$25.3M-32.6% | -$19.1M-19.1% | -$16.0M+17.0% | -$19.3M-7.3% | -$18.0M+21.8% | -$23.0M+14.3% | -$26.9M+39.7% | -$44.6M+7.6% | -$48.2M-30.5% | -$36.9M-20.0% | -$30.8M+26.2% | -$41.7M |
| Capital Expenditures | N/A | N/A | $0 | $0-100.0% | $21K | $0 | $0-100.0% | $70K+1300.0% | $5K-91.2% | $57K-34.5% | $87K-16.3% | $104K+215.2% | $33K-81.8% | $181K |
| Free Cash Flow | N/A | N/A | -$25.3M-32.6% | -$19.1M-18.9% | -$16.0M+16.9% | -$19.3M-7.3% | -$18.0M+22.0% | -$23.1M+14.0% | -$26.9M+39.8% | -$44.6M+7.6% | -$48.3M-30.4% | -$37.0M-20.2% | -$30.8M+26.4% | -$41.9M |
| Investing Cash Flow | N/A | $0 | $0-100.0% | $4.4M+21071.4% | -$21K | $0 | $0-100.0% | $242K+3357.1% | $7K+128.0% | -$25K+69.9% | -$83K | N/A | N/A | N/A |
| Financing Cash Flow | N/A | $77.4M+47.2% | $52.6M+338.5% | $12.0M-18.7% | $14.8M-45.3% | $27.0M+38.6% | $19.5M-14.9% | $22.9M+37.7% | $16.6M+121.5% | $7.5M-36.4% | $11.8M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
VTVT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -2377.6% | N/A | -1116.9% | -540.9% | -184.8% | -755.9% | -159.4% | -17416.5% | -8678.2% | -7349.1% | -1865.5% | -3671.4% |
| Net Margin | N/A | -1815.3% | N/A | -949.6% | -324.3% | -132.5% | -471.9% | -63.6% | -5547.8% | -2579.2% | -5298.3% | -2330.6% | -4938.8% |
| Return on Equity | -41.9%+109.5pp | -151.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -30.0%+18.3pp | -48.3%+135.5pp | -183.8%-126.1pp | -57.7%-6.7pp | -51.0%+6.5pp | -57.5%+83.3pp | -140.8%-48.3pp | -92.4%-34.6pp | -57.8%-27.8pp | -30.0%0.0pp | -30.0%+248.7pp | -278.8% | N/A |
| Current Ratio | 13.54+6.2x | 7.34+6.3x | 1.00-2.5x | 3.52+1.7x | 1.84+0.7x | 1.13+0.9x | 0.210.0x | 0.18-0.6x | 0.76-3.8x | 4.56-7.0x | 11.54+11.3x | 0.23 | N/A |
| Debt-to-Equity | 0.40-1.6x | 1.96 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | -2488.4% | N/A | -795.0% | -482.1% | -280.6% | -835.3% | -216.0% | -15332.3% | -7617.7% | -7138.7% | -1989.2% | -4289.4% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Vtv Therapeutics Ranks
Frequently Asked Questions
What is Vtv Therapeutics's annual revenue?
Vtv Therapeutics (VTVT) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vtv Therapeutics's revenue growing?
Vtv Therapeutics (VTVT) revenue declined by 100.0% year-over-year, from $1.0M to $0 in fiscal year 2025.
Is Vtv Therapeutics profitable?
No, Vtv Therapeutics (VTVT) reported a net income of -$27.0M in fiscal year 2025.
What is Vtv Therapeutics's EBITDA?
Vtv Therapeutics (VTVT) had EBITDA of -$32.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Vtv Therapeutics's return on equity (ROE)?
Vtv Therapeutics (VTVT) has a return on equity of -41.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Vtv Therapeutics's operating cash flow?
Vtv Therapeutics (VTVT) recorded an outflow of $25.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Vtv Therapeutics's total assets?
Vtv Therapeutics (VTVT) had $89.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Vtv Therapeutics spend on research and development?
Vtv Therapeutics (VTVT) invested $17.9M in research and development during fiscal year 2025.
What is Vtv Therapeutics's current ratio?
Vtv Therapeutics (VTVT) had a current ratio of 13.54 as of fiscal year 2025, which is generally considered healthy.
What is Vtv Therapeutics's debt-to-equity ratio?
Vtv Therapeutics (VTVT) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vtv Therapeutics's return on assets (ROA)?
Vtv Therapeutics (VTVT) had a return on assets of -30.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Vtv Therapeutics's cash runway?
Based on fiscal year 2025 data, Vtv Therapeutics (VTVT) had $88.9M in cash against an annual operating cash burn of $25.3M. This gives an estimated cash runway of approximately 42 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Vtv Therapeutics's Altman Z-Score?
Vtv Therapeutics (VTVT) has an Altman Z-Score of -2.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Vtv Therapeutics's Piotroski F-Score?
Vtv Therapeutics (VTVT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vtv Therapeutics's earnings high quality?
Vtv Therapeutics (VTVT) reported a net loss of $27.0M while operations used $25.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Vtv Therapeutics cover its interest payments?
Vtv Therapeutics (VTVT) reported an operating loss of $32.8M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.